Cerebrovascular Diseases and Stroke Research
The Cerebrovascular Disease and Stroke team has a robust portfolio in leading federally funded comparative effectiveness (CER) and patient-centered outcomes studies. Clinical research activities have addressed crucial questions regarding carotid disease, intracranial large vessel disease, the effect of glucose control & hypertension in acute stroke patients, and the use of antiplatelet and anticoagulant medication. A notable contribution includes research leading to the wide adoption of alteplase, the only FDA-approved medical therapy, in acute ischemic stroke and other cerebrovascular diseases.
The section is building a real-world data platform to advance research in vascular contributions to cognitive impairment & dementia and developing patient-centered prediction tools to empower stroke patients regarding stroke care and prevention. Faculty also lead the Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry, driving nationwide quality improvement efforts to build upon the existing infrastructure of the nation's largest ongoing stroke registry AHA’s "Get With The Guidelines."
Cerebrovascular Disease Researchers
- IST | Lancet 1997
- NASCET | NEJM 1998
- AAASPS | JAMA 2003
- VISP | JAMA 2004
- WASID | NEJM 2005
- SONIA | Neurology 2007
- SAMMPRIS | NEJM 2011
- SWISS | Stroke 2011
- COSS | JAMA 2011
- SPS3 | NEJM 2013
- CRYSTAL AF | NEJM 2014
- IRIS | NEJM 2016
- NAVIGATE ESUS | NEJM 2018
- POINT | NEJM 2018
- RHAPSODY | Annals of Neurology 2019
- MyRIAD | Journal of Stroke and Cerebrovascular Diseases 2021
Currently Enrolling
- Ty Shang, M.D., Ph.D., is the site PI of OCEANIC-STROKE. This Phase III study is a multicenter, international, randomized, placebo-controlled, double-blind, parallel-group study. The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy.
- Brain Oxygen Optimization in Severe TBI Phase III (BOOST3), is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone.
Research Collaborations
ECG Monitoring
In collaboration with Cardiology, our team has conducted clinical trials to improve the detection of atrial fibrillation after a cryptogenic stroke. We found that ECG monitoring with an ICM was superior to conventional follow-up for detecting atrial fibrillation after cryptogenic stroke.
Dallas Heart Study
Our team has been involved in the Dallas Heart Study, a multidisciplinary study of ethnic differences in cardiovascular health.
Lone Star Stroke Research Consortium (LSS)
A novel collaboration among leading medical research institutions in Texas to improve the health of Texans affected by stroke and cerebrovascular disease. The mission of LSS is to establish a state-wide network for patient-centered stroke research and therapeutic trials within Texas that links academic health institutions with proven expertise in stroke research to community stroke centers. The LSS Research Consortium has established a robust, geographically diverse, network of sites that has the capability and infrastructure to implement studies quickly throughout Texas.
CuringComa Campaign
The focus of the Curing Coma Campaign ACute cOma PragMatic Prospective ObSErvational (COMPOSE) Study is to:
- Accurately define the natural history of coma recovery in the acute phase of neurological injury
- Establish a prototype hub-spoke-based research network with central governance utilizing database infrastructure under the Curing Coma Campaign, and
- Explore the variability in care influencing patient outcomes.
We propose a prospective, pragmatic, multicenter study to recruit 425 patients with acute coma to detail the natural history of coma recovery. Ours will be the first study to evaluate recovery in coma from a variety of etiologies, in a global diverse population utilizing standardized, pragmatic outcome measures.
Program Questions or Collaboration:
Taylor Norman
Stroke Program Operations Manager
Taylor.Norman@utsouthwestern.edu